Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Probable ATP Dependent R Helicase DDX58 (DEAD Box Protein 58 or RIG I Like Receptor 1 or Retinoic Acid Inducible Gene 1 Protein or DDX58 or EC 3.6.4.13) - Overview
Probable ATP Dependent R Helicase DDX58 (DEAD Box Protein 58 or RIG I Like Receptor 1 or Retinoic Acid Inducible Gene 1 Protein or DDX58 or EC 3.6.4.13) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Probable ATP Dependent R Helicase DDX58 (DEAD Box Protein 58 or RIG I Like Receptor 1 or Retinoic Acid Inducible Gene 1 Protein or DDX58 or EC 3.6.4.13) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Probable ATP Dependent R Helicase DDX58 (DEAD Box Protein 58 or RIG I Like Receptor 1 or Retinoic Acid Inducible Gene 1 Protein or DDX58 or EC 3.6.4.13) - Companies Involved in Therapeutics Development
Bioncotech Therapeutics SL
Kineta Inc
Merck & Co Inc
Sires LLC
Spring Bank Pharmaceuticals Inc
Vycellix Inc
Probable ATP Dependent R Helicase DDX58 (DEAD Box Protein 58 or RIG I Like Receptor 1 or Retinoic Acid Inducible Gene 1 Protein or DDX58 or EC 3.6.4.13) - Drug Profiles
(irigivir soproxil + tenofovir disoproxil fumarate) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Antisense Ri Oligonucleotide to Agonize RIG1 for Solid Tumors - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BO-112 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
irigivir soproxil - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KIN-1312 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MK-4621 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SB-44 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SB-9400 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SLR-20 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Modulate RIG-I for Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Target RIG-I for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VY-201 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VY-202 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Probable ATP Dependent R Helicase DDX58 (DEAD Box Protein 58 or RIG I Like Receptor 1 or Retinoic Acid Inducible Gene 1 Protein or DDX58 or EC 3.6.4.13) - Dormant Products
Probable ATP Dependent R Helicase DDX58 (DEAD Box Protein 58 or RIG I Like Receptor 1 or Retinoic Acid Inducible Gene 1 Protein or DDX58 or EC 3.6.4.13) - Product Development Milestones
Featured News & Press Releases
Dec 12, 2019: Bioncotech Therapeutics phase I BO-112 data presented at ESMO Immuno-Oncology Congress 2019
Oct 17, 2019: Spring Bank announces interim top-line results from the first cohort of the phase 2 trial evaluating low-dose Irigivir plus Vemlidy in Chronic Hepatitis B Patients
Oct 14, 2019: A Yale-developed drug shows promise as immune therapy for cancer
Jun 06, 2019: Spring Bank Announces Presentation of Promising Results from Study Highlighting Immune-Activation with Irigivir 400mg
Apr 12, 2019: Spring Bank announces positive results from the recently completed phase 2 chronic hepatitis B ACHIEVE Trial and additiol Irigivir studies
Apr 10, 2019: Spring Bank to host a conference call to discuss Irigivir data presented at the Intertiol Liver Congress (EASL 2019)
Mar 28, 2019: Spring Bank announces Irigivir abstracts accepted for oral and poster presentations at The Intertiol Liver Congress (EASL 2019)
Nov 09, 2018: Spring Bank announces additiol Irigivir results at AASLD Conference
Oct 09, 2018: Merck to present data on tumor drug candidate MK-4621 at ESMO 2018
Oct 03, 2018: Spring Bank announces Irigivir data presentations at AASLD Conference
Aug 02, 2018: Spring Bank announces positive study results from the Irigivir ACHIEVE trial
Apr 10, 2018: Spring Bank Announces Expanded Irigivir Data from the ACHIEVE Trial to Be Presented at The Intertiol Liver Congress
Mar 14, 2018: Spring Bank Announces Presentation of Combined Irigivir 25 mg and 50 mg 12 and 24 Week ACHIEVE Results Demonstrating Enhanced Anti-Viral Efficacy in HBeAg-Negative Patients
Nov 15, 2017: Spring Bank Pharmaceuticals Announces Positive Top-Line Results from the Second Cohort of Part A of the Phase 2 ACHIEVE Trial
Oct 20, 2017: Spring Bank Pharmaceuticals Announces Additiol Irigivir (formerly SB 9200) Results from the ACHIEVE Trial in HBV Patients at AASLD Conference
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures


Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Top 10 Indications, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Routes of Administration, H2 2019
Number of Products by Stage and Routes of Administration, H2 2019
Number of Products by Molecule Types, H2 2019
Number of Products by Stage and Molecule Types, H2 2019


List of Tables


Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indication, H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Number of Products under Investigation by Universities/Institutes, H2 2019
Products under Investigation by Universities/Institutes, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by Bioncotech Therapeutics SL, H2 2019
Pipeline by Kineta Inc, H2 2019
Pipeline by Merck & Co Inc, H2 2019
Pipeline by Sirenas LLC, H2 2019
Pipeline by Spring Bank Pharmaceuticals Inc, H2 2019
Pipeline by Vycellix Inc, H2 2019
Dormant Projects, H2 2019